Biohaven (BHVN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Definitive additional proxy materials filed, indicating updates or supplemental information for shareholders.
Voting matters and shareholder proposals
Proxy materials relate to matters requiring shareholder voting under Section 14(a) of the Securities Exchange Act.
Shareholder rights and capital structure
Filing includes information on securities classes and aggregate numbers relevant to voting and transactions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Biohaven
- Votes will be held on director elections, auditor ratification, and executive compensation.BHVN
Proxy Filing13 Mar 2026 - Director elections, auditor ratification, and Say-on-Pay headline a year of strategic execution.BHVNProxy Filing13 Mar 2026
- First-in-class degraders, novel CNS and obesity therapies, and oncology assets advance toward pivotal trials in 2026.BHVN44th Annual J.P. Morgan Healthcare Conference presentation2 Mar 2026
- Net loss narrowed as cost optimization and capital raises support pivotal trials in 2026.BHVNQ4 20252 Mar 2026
- Troriluzole slowed SCA progression by up to 70% over 3 years, with robust safety and efficacy.BHVNStudy Result20 Jan 2026
- Proxy covers director elections, auditor ratification, executive pay, and governance highlights.BHVNProxy Filing1 Dec 2025
- Q3 2025 saw a $173.4M net loss, major R&D cuts, and $263.8M in cash for near-term operations.BHVNQ3 202510 Nov 2025
- Lead programs in SCA, epilepsy, and precision immunology drive late-stage pipeline momentum.BHVNR&D Day 2025 Presentation5 Nov 2025
- Late-stage pipeline advances in SCA, neurology, and oncology with strong clinical data.BHVNCorporate Presentation5 Nov 2025